Inizia
Invesco QQQ Trust, Series 1

Markets research 01.05.2026

116
🌏Markets:
  • SPY +1.86 +0.26%(pre/m)
  • QQQ −0.31 −0.05%(pre/m)

🆕Economic News:
  • 10:00 USA – ISM Manufacturing Employment
  • 10:00 USA – ISM Manufacturing PMI

📈 Gap Ups
Reaction to earnings/guidance:

Other news:
  • AAPL approved a new buyback of up to $100 billion and increased its dividend.
  • VEEV Set to Join S&P 500 on May 6 / replacing $NYSE:CTRA (DVN is acquiring CTRA)
  • Investor sentiment across cannabis stocks improved after the U.S. Justice Department moved state-regulated marijuana toward Schedule III. AKAN delivered one of the biggest rallies in April among cannabis stocks, rocketing ~2200%
  • CUE Announces $30 Million Private Placement
  • NVDA MSFT AMZN SIGN PENTAGON AI DEALS

📉 Gap Downs
Reaction to earnings/guidance:

Other news:
  • Morgan Stanley Downgrades ELF to Equalweight from Overweight, Lowers PT to $67 from $80

‼️Additional
  • Today, Trump is expected to justify to Congress the continuation of the military operation against Iran.
    -- Most analysts believe Congress will give the “green light” for the continuation of hostilities.

🏢IPO
  • COAG – Hemab Therapeutics Holdings, Inc.
    Company develops under-the-skin treatments for rare blood clotting disorders. Lead drug, sutacimig / HMB-001, has completed Phase 2 and is ready for Phase 3 in Glanzmann thrombasthenia, a rare bleeding disorder. The company also has earlier programs for Factor VII deficiency and Von Willebrand Disease. No revenue yet.
  • Price: $18.00
  • Shares: 16.8M
  • Raised: $301.5M
    LTM:
  • Revenue: $0
  • Net Income: -$63.9M
  • Comparable public companies: BMRN, QURE, RARE, ALNY, NVO

  • SPTX – Seaport Therapeutics
    Company develops oral treatments for depression, anxiety and other neuropsychiatric disorders. Its platform is designed to make existing drug mechanisms work better as pills by improving absorption and reducing side effects. Lead candidate, GlyphAllo, is being tested for major depressive disorder, with key Phase 2b data expected in 2027. Second candidate targets anxiety and sleep-related symptoms.
  • Price: $18.00
  • Shares: 14.2M
  • Raised: $254.9M
    LTM:
  • Revenue: $0
  • Net Income: -$74.9M
  • Comparable public companies: SAGE, AXSM, CMPS, ATAI, GHRS


📋 List of tickers involved:
SPY QQQ AAPL TEAM TWLO RDDT EL NVT MRNA ZETA ROKU VEEV $NYSE:CTRA DVN AKAN CUE NVDA MSFT AMZN RBLX SMMT WDC SNDK RYAN AXTI NWG ATMU AMGN ELF COAG SPTX

Best regards – hi2morrow team.
hi2morrow_team
Trading | NYSE | NASDAQ ⚡
A community of active traders from hi2morrow
✅ Take the trading firm evaluation program: hi2morrow.com/
✅ Join the club: hi2morrow.com/club
✅ Trading academy: hi2morrow.com/course
Anche su:
Beyond Technical Analysis

Declinazione di responsabilità

Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Beyond Technical Analysis
hi2morrow_team
Trading | NYSE | NASDAQ ⚡
A community of active traders from hi2morrow
✅ Take the trading firm evaluation program: hi2morrow.com/
✅ Join the club: hi2morrow.com/club
✅ Trading academy: hi2morrow.com/course
Anche su:

Declinazione di responsabilità

Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.